Evidence map›Paper›PMID 26808374›Full record

ArticlePLoS computational biology2016

Adaptive Landscape by Environment Interactions Dictate Evolutionary Dynamics in Models of Drug Resistance.

C Brandon Ogbunugafor, C Scott Wylie, Ibrahim Diakite, Daniel M Weinreich, Daniel L Hartl

Abstract read
In one paragraph

Article in PLoS computational biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Deconstructing empirical fitness seascapes across scales of granularity.bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Inference and visualization of complex genotype-phenotype maps withbioRxiv : the preprint server for biology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Epistasis-mediated compensatory evolution in a fitness landscape with adaptational tradeoffs.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  15. Review
  16. Article
  17. Reinforcement learning informs optimal treatment strategies to limit antibiotic resistance.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  18. Evolution Under Thermal Stress AffectsbioRxiv : the preprint server for biology · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

C Brandon OgbunugaforDepartment of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, United States of America.
C Scott WylieDepartment of Ecology and Evolutionary Biology, Brown University, Providence, Rhode Island, United States of America.
Ibrahim DiakiteDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
Daniel M WeinreichDepartment of Ecology and Evolutionary Biology, Brown University, Providence, Rhode Island, United States of America.
Daniel L HartlDepartment of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, United States of America.

Funding

Evolutionary medicine in the development of antimalaria drugsR01AI106734 · NIAID · HARVARD UNIVERSITY · PI HARTL, DANIEL L · 2014 to 2017
$1.6M
NIAID NIH HHS AI106734NIAID NIH HHS R01 AI106734
6 · The paper itself

Abstract

The adaptive landscape analogy has found practical use in recent years, as many have explored how their understanding can inform therapeutic strategies that subvert the evolution of drug resistance. A major barrier to applications of these concepts is a lack of detail concerning how the environment affects adaptive landscape topography, and consequently, the outcome of drug treatment. Here we combine empirical data, evolutionary theory, and computer simulations towards dissecting adaptive landscape by environment interactions for the evolution of drug resistance in two dimensions-drug concentration and drug type. We do so by studying the resistance mediated by Plasmodium falciparum dihydrofolate reductase (DHFR) to two related inhibitors-pyrimethamine and cycloguanil-across a breadth of drug concentrations. We first examine whether the adaptive landscapes for the two drugs are consistent with common definitions of cross-resistance. We then reconstruct all accessible pathways across the landscape, observing how their structure changes with drug environment. We offer a mechanism for non-linearity in the topography of accessible pathways by calculating of the interaction between mutation effects and drug environment, which reveals rampant patterns of epistasis. We then simulate evolution in several different drug environments to observe how these individual mutation effects (and patterns of epistasis) influence paths taken at evolutionary "forks in the road" that dictate adaptive dynamics in silico. In doing so, we reveal how classic metrics like the IC50 and minimal inhibitory concentration (MIC) are dubious proxies for understanding how evolution will occur across drug environments. We also consider how the findings reveal ambiguities in the cross-resistance concept, as subtle differences in adaptive landscape topography between otherwise equivalent drugs can drive drastically different evolutionary outcomes. Summarizing, we discuss the results with regards to their basic contribution to the study of empirical adaptive landscapes, and in terms of how they inform new models for the evolution of drug resistance.

Indexed as

AntimalarialsComputational BiologyDrug ResistanceEvolution, MolecularHumansInhibitory Concentration 50Malaria, FalciparumModels, BiologicalMutationPlasmodium falciparumProguanilPyrimethamineTriazinesAntimalarialscycloguanilProguanilPyrimethamineTriazines

Identifiers

PMID26808374
PMCPMC4726534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.